CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Contrast Ultrasound vs. Abbreviated MRI for Detection of HCC in Patients With Indeterminate Liver Nodules
University of Texas Southwestern Medical Center
600 participants
Nov 28, 2023
INTERVENTIONAL
Conditions
Summary
The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.
Eligibility
Inclusion Criteria2
- Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
- Adults 18 years old and above
Exclusion Criteria6
- Patients post liver transplantation
- Patients with concurrent or prior HCC (LR-5 or biopsy proven)
- other liver cancer including cholangiocarcinoma
- Patients with any active extra-hepatic malignancy
- Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit
- Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia
Interventions
Contrast-enhanced ultrasound (CEUS)
contrast enhanced abbreviated MRI (AMRI)
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06184152